In non-small-cell lung cancer (NSCLC), inhibition of JAK2 has been shown to reduce STAT3 phosphorylation, a critical step in preventing its nuclear translocation and subsequent transcriptional activation of oncogenic genes. Here, JAK2 is linked to non-small cell lung carcinoma.